Molecular mechanisms underlying the effectiveness of triiodothyroacetic acid (Triac) in patients with resistance to thyroid hormone β (RTHβ): a multicentre, international, retrospective cohort study.
Abstract
Background
Disease features in resistance to thyroid hormone beta (RTHβ), caused by THRB mutations, arise from insensitivity to thyroid hormone in tissues expressing thyroid hormone receptor (TR)β and from lifelong thyrotoxic effects in TRα1-expressing tissues, posing substantial cardiovascular morbidity/mortality. The T3-analogue triiodothyroacetic acid (Triac) holds potential as an effective treatment. Systematic data on Triac therapy in RTHβ are lacking, and the mechanisms through which Triac acts are unclear. This study aims to elucidate these knowledge gaps.Methods
Clinical and biochemical data were obtained through an, international retrospective cohort study in patients with RTHβ. Transcriptional activity of all TRβ mutants, on the background of the pituitary-expressed β2 receptor isoform and positively (DR+4-TRE) or negatively (TSHα-TRE) regulated reporter genes plus T3 or Triac, was studied. Thyroid function and TSH responses to T3 and Triac were tested in zebrafish expressing TRβ mutants.Findings
We collected data from 28 patients with RTHβ (range: 0.4-73.1 years) with 18 unique mutations treated with Triac in 6 centres. Triac reduced TSH (by 43%) and FT4 (by 37%) concentrations in all heterozygous patients, supported by consistent findings in zebrafish. Our functional studies showed that TRβ2 mutants exhibited reduced (all) or absent (G432del) T3-dependent transcriptional activity, with similar EC50 and IC50 values for T3 and Triac, except for R316H, which showed a 5-times lower EC50/IC50 value for Triac compared to T3.Interpretation
In this international, multicentre study we have documented that Triac lowers elevated FT4 concentrations in patients with RTHβ effectively. Integrating our clinical and molecular observations we suggest that Triac can act via different modes of action, with activation of the wild-type receptor being a relevant mechanism. Our study may inform clinical management and could shape future interventional studies in patients with RTHβ.Funding
Financial support is acknowledged by WL (Affiliated Hospital of Southwest Medical University) WEV (ZonMw (Dutch Research Council, VIDI 09150172210071)), KC (Wellcome (210755/Z/18/Z), NIHR Cambridge Biomedical Research Centre (NIHR20312) and Medical Research Council United Kingdom (MRC_MU_UU_00014/40)), LP (European Union - Next Generation EU - NRRP M6C2 - Investment 2.1 Enhancement and strengthening of biomedical research in the NHS (code: PNRR-MR1-2022-12375726).
Related
- Brain injury after single fetal demise in monochorionic twin pregnancies: an international multicentre retrospective cohort study
- Evaluation of devices used for endovascular repair of ruptured abdominal aortic aneurysms in the international consortium of vascular registries: an international, retrospective, multicentre, single-arm, open-label performance goal study.
- Real-World Effectiveness and Safety of Sofosbuvir-Based Therapy in Chinese Children and Adolescents With Chronic HCV Infection: A Retrospective Multicentre Study.
- Videolaryngoscopy versus direct laryngoscopy for tracheal intubation in paediatric surgery: the VIDEOKIDS pragmatic international multicentre randomised trial study protocol.
- Effectiveness and safety of electroacupuncture as an adjunct to guideline-based usual care for acute lumbar disc herniation: a multicentre, randomised, sham-controlled trial protocol.
BibTeX
@article{liao2026molecular,
title = {{Molecular mechanisms underlying the effectiveness of triiodothyroacetic acid (Triac) in patients with resistance to thyroid hormone β (RTHβ): a multicentre, international, retrospective cohort study.}},
author = {Wenjun Liao and Federica Marelli and Carla Moran and Irene Campi and Stefan Groeneweg and Zainaba Mohamed and Eman Kamaleldeen and Raja Padidela and Catharina Olivius and Luuk Oosterkamp and Selmar Leeuwenburgh and Greta Lyons and Robin P. Peeters and Krishna Chatterjee and Luca Persani and Marcel Meima and W. Edward Visser},
journal = {EBioMedicine},
year = {2026},
month = oct,
doi = {10.1016/j.ebiom.2026.106512},
url = {https://europepmc.org/article/MED/42874294},
note = {CC BY},
}
RIS
TY - JOUR
TI - Molecular mechanisms underlying the effectiveness of triiodothyroacetic acid (Triac) in patients with resistance to thyroid hormone β (RTHβ): a multicentre, international, retrospective cohort study.
AU - Wenjun Liao
AU - Federica Marelli
AU - Carla Moran
AU - Irene Campi
AU - Stefan Groeneweg
AU - Zainaba Mohamed
AU - Eman Kamaleldeen
AU - Raja Padidela
AU - Catharina Olivius
AU - Luuk Oosterkamp
AU - Selmar Leeuwenburgh
AU - Greta Lyons
AU - Robin P. Peeters
AU - Krishna Chatterjee
AU - Luca Persani
AU - Marcel Meima
AU - W. Edward Visser
PY - 2026
DA - 2026/10/14
JO - EBioMedicine
DO - 10.1016/j.ebiom.2026.106512
UR - https://europepmc.org/article/MED/42874294
AB - Background Disease features in resistance to thyroid hormone beta (RTHβ), caused by THRB mutations, arise from insensitivity to thyroid hormone in tissues expressing thyroid hormone receptor (TR)β and from lifelong thyrotoxic effects in TRα1-expressing tissues, posing substantial cardiovascular morbidity/mortality. The T3-analogue triiodothyroacetic acid (Triac) holds potential as an effective treatment. Systematic data on Triac therapy in RTHβ are lacking, and the mechanisms through which Triac acts are unclear. This study aims to elucidate these knowledge gaps.Methods Clinical and biochemical data were obtained through an, international retrospective cohort study in patients with RTHβ. Transcriptional activity of all TRβ mutants, on the background of the pituitary-expressed β2 receptor isoform and positively (DR+4-TRE) or negatively (TSHα-TRE) regulated reporter genes plus T3 or Triac, was studied. Thyroid function and TSH responses to T3 and Triac were tested in zebrafish expressing TRβ mutants.Findings We collected data from 28 patients with RTHβ (range: 0.4-73.1 years) with 18 unique mutations treated with Triac in 6 centres. Triac reduced TSH (by 43%) and FT4 (by 37%) concentrations in all heterozygous patients, supported by consistent findings in zebrafish. Our functional studies showed that TRβ2 mutants exhibited reduced (all) or absent (G432del) T3-dependent transcriptional activity, with similar EC50 and IC50 values for T3 and Triac, except for R316H, which showed a 5-times lower EC50/IC50 value for Triac compared to T3.Interpretation In this international, multicentre study we have documented that Triac lowers elevated FT4 concentrations in patients with RTHβ effectively. Integrating our clinical and molecular observations we suggest that Triac can act via different modes of action, with activation of the wild-type receptor being a relevant mechanism. Our study may inform clinical management and could shape future interventional studies in patients with RTHβ.Funding Financial support is acknowledged by WL (Affiliated Hospital of Southwest Medical University) WEV (ZonMw (Dutch Research Council, VIDI 09150172210071)), KC (Wellcome (210755/Z/18/Z), NIHR Cambridge Biomedical Research Centre (NIHR20312) and Medical Research Council United Kingdom (MRC_MU_UU_00014/40)), LP (European Union - Next Generation EU - NRRP M6C2 - Investment 2.1 Enhancement and strengthening of biomedical research in the NHS (code: PNRR-MR1-2022-12375726).
SN - 2352-3964
ER -